EUA

EUA. An Emergency Use Authorization is a mechanism by which the Food and Drug Administration can permit the use of unapproved medical products during a declared public health emergency. It is a legal tool designed to expedite the availability of critical countermeasures, such as vaccines, therapeutics, and diagnostic tests, when there are no adequate, approved, and available alternatives. The authority is granted under Section 564 of the Federal Food, Drug, and Cosmetic Act, as amended by the Project BioShield Act of 2004.

Definition and legal basis

The legal foundation for an Emergency Use Authorization stems from specific amendments to the Federal Food, Drug, and Cosmetic Act. Following concerns about bioterrorism highlighted by the 2001 anthrax attacks, the Project BioShield Act of 2004 formally established the EUA authority. This was later refined by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013. The power to declare an emergency that triggers the EUA pathway rests with the Secretary of Health and Human Services, often following guidance from agencies like the Centers for Disease Control and Prevention. The statute requires that the known and potential benefits of the product outweigh its known and potential risks, and that it may be effective for its intended use.

Historical use and examples

Prior to the COVID-19 pandemic, EUAs were primarily issued for threats like avian influenza, the 2009 H1N1 pandemic, the Zika virus outbreak, and the 2014 Ebola epidemic in West Africa. During the COVID-19 crisis, the mechanism saw unprecedented use, authorizing numerous diagnostics, including those from Abbott Laboratories and Roche, therapeutics like remdesivir and monoclonal antibody treatments from Regeneron, and ultimately vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson. The authorization of convalescent plasma also occurred under this framework.

Procedure and criteria for issuance

The process begins with a formal request submitted to the Food and Drug Administration by a product sponsor, such as a pharmaceutical company or a diagnostic manufacturer. The FDA then evaluates the submission, which must include all available scientific evidence, including data from clinical trials and manufacturing information. A key advisory committee, the Vaccines and Related Biological Products Advisory Committee, often reviews vaccine data. The decision to issue an EUA requires a determination that the product meets the statutory safety and benefit-risk criteria, and that it can be manufactured consistently. Conditions of authorization may include mandatory fact sheets for providers and patients and continued data collection.

Comparison with other regulatory mechanisms

An EUA is distinct from a full FDA approval, which requires more comprehensive data and a longer review period under a New Drug Application or Biologics License Application. It is also different from a Compassionate Use protocol, which is for individual patient access to investigational drugs. Compared to the World Health Organization's Emergency Use Listing, the EUA is a national regulatory action specific to the United States. The European Medicines Agency employs a similar but distinct mechanism called a Conditional Marketing Authorisation.

Controversies and criticisms

The EUA process has faced significant scrutiny, particularly during the COVID-19 pandemic. Controversies have included political pressure perceived during the authorization of therapies like hydroxychloroquine, which was later revoked, and allegations of rushed review timelines. The communication of EUA status versus full approval led to public confusion, a situation highlighted during the rollout of COVID-19 vaccines. Some critics, including members of the House Select Subcommittee on the Coronavirus Crisis, have argued that the Trump administration exerted undue influence on the FDA and the CDC.

Impact on public health and policy

The EUA mechanism has profoundly shaped the response to modern public health crises, drastically accelerating the deployment of countermeasures. It enabled the rapid scale-up of testing during the COVID-19 pandemic and facilitated the historic development and distribution of mRNA vaccines within a year. The framework has influenced global regulatory policy, with many nations adopting similar expedited pathways. Debates over the EUA process have also spurred legislative discussions about permanent reforms to the Food and Drug Administration's emergency authorities for future pandemics.

Category:Food and Drug Administration Category:United States public health legislation Category:Emergency management